Pacira BioSciences
PCRX
PCRX
187 hedge funds and large institutions have $2.01B invested in Pacira BioSciences in 2018 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 53 increasing their positions, 59 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
187
Holders Change
+31
Holders Change %
+19.87%
% of All Funds
4.28%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
46
Increased
53
Reduced
59
Closed
15
Calls
$42.5M
Puts
$44.4M
Net Calls
-$1.95M
Net Calls Change
+$13.5M
Top Buyers
| 1 |
1
Invesco
Atlanta,
Georgia
|
$20.7M |
| 2 |
2
Millennium Management
New York
|
$70.2M |
| 3 |
3
Goldman Sachs
New York
|
$25.4M |
| 4 |
PC
4
Polar Capital
London,
United Kingdom
|
$13.9M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$179M |
Top Sellers
| 1 |
PC
1
PointState Capital
New York
|
$12.6M |
| 2 |
ACA
2
Avoro Capital Advisors
New York
|
$20.3M |
| 3 |
HM
3
HealthCor Management
New York
|
$95.6M |
| 4 |
DCM
4
Daruma Capital Management
New York
|
$25M |
| 5 |
ECP
5
Elk Creek Partners
Denver,
Colorado
|
$35.7M |
